ADGI:NSD-Adagio Therapeutics Inc. Common Stock (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.70

Change

0.00 (0.00)%

Market Cap

USD 0.63B

Volume

7.79M

Avg Analyst Target

USD 9.00 (+57.89%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Adagio Therapeutics Inc. Common Stock (ADGI) Stock Analysis:
Based on the Adagio Therapeutics Inc. Common Stock stock forecasts from 4 analysts, the average analyst target price for Adagio Therapeutics Inc. Common Stock is USD 9.00 over the next 12 months. Adagio Therapeutics Inc. Common Stock’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Adagio Therapeutics Inc. Common Stock is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Adagio Therapeutics Inc. Common Stock’s stock price was USD 5.70. Adagio Therapeutics Inc. Common Stock’s stock price has changed by -0.41% over the past week, -5.78% over the past month and +0.00% over the last year.

About

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Its lead product candidate is the ADG20, a neutralizing antibody that is i ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

N/A

USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD59.51B 28.07 15.97
BNTX BioNTech SE

N/A

USD47.53B 6.14 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

N/A

USD25.07B 55.02 44.86
BGNE BeiGene Ltd

N/A

USD24.70B N/A N/A
GMAB Genmab A/S

N/A

USD23.58B 53.39 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

N/A

USD17.76B N/A N/A

ETFs Containing ADGI

Symbol Name Weight Mer Price(Change) Market Cap
GERM ETF Managers Trust - ETFM.. 0.00 % 0.68 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.49% 15% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.49% 15% F 7% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.63B 72% C- 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -25.39 87% B+ 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital N/A N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.41 90% A- 86% B
Short Percent 11.28% 15% F 15% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.